4.5 Article

Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis

期刊

AMERICAN JOURNAL OF NEURORADIOLOGY
卷 34, 期 3, 页码 498-504

出版社

AMER SOC NEURORADIOLOGY
DOI: 10.3174/ajnr.A3262

关键词

-

资金

  1. BiogenIdec AB
  2. Swedish Association of Persons
  3. Neurologic Disabilities
  4. Objective 2 Norra Norrland-EU Structural Fund

向作者/读者索取更多资源

BACKGROUND AND PURPOSE: Brain atrophy is a manifestation of tissue damage in MS. Reduction in brain parenchymal fraction is an accepted marker of brain atrophy. In this study, the approach of synthetic tissue mapping was applied, in which brain parenchymal fraction was automatically calculated based on absolute quantification of the tissue relaxation rates R1 and R2 and the proton attenuation. MATERIALS AND METHODS: The BPF values of 99 patients with MS and 35 control subjects were determined by using SyMap and tested in relationship to clinical variables. A subset of 5 patients with MS and 5 control subjects were also analyzed with a manual segmentation technique as a reference. Reproducibility of SyMap was assessed in a separate group of 6 healthy subjects, each scanned 6 consecutive times. RESULTS: Patients with MS had significantly lower BPF (0.852 0.0041, mean +/- SE) compared with control subjects (0.890 +/- 0.0040). Significant linear relationships between BPF and age, disease duration, and Expanded Disability Status Scale scores were observed (P < .001). A strong correlation existed between SyMap and the reference method (r = 0.96; P < .001) with no significant difference in mean BPF. Coefficient of variation of repeated SyMap BPF measurements was 0.45%. Scan time was <6 minutes, and postprocessing time was <2 minutes. CONCLUSIONS: SyMap is a valid and reproducible method for determining BPF in MS within a clinically acceptable scan time and postprocessing time. Results are highly congruent with those described using other methods and show high agreement with the manual reference method.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS

Mathias Granqvist, Joachim Burman, Martin Gunnarsson, Jan Lycke, Petra Nilsson, Tomas Olsson, Peter Sundstrom, Anders Svenningsson, Magnus Vrethem, Thomas Frisell, Fredrik Piehl

MULTIPLE SCLEROSIS JOURNAL (2020)

Article Clinical Neurology

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Thomas Frisell

JAMA NEUROLOGY (2020)

Article Clinical Neurology

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Thomas Frisell

ANNALS OF NEUROLOGY (2020)

Article Clinical Neurology

Prevention of post-dural puncture headache: a randomized controlled trial

J. Salzer, G. Granasen, P. Sundstrom, M. Vagberg, A. Svenningsson

EUROPEAN JOURNAL OF NEUROLOGY (2020)

Article Endocrinology & Metabolism

Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry

Henrik Carlsson, Sandy Abujrais, Stephanie Herman, Payam Emami Khoonsari, Torbjorn Akerfeldt, Anders Svenningsson, Joachim Burman, Kim Kultima

METABOLOMICS (2020)

Article Clinical Neurology

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension

Joakim Bergman, Joachim Burman, Tommy Bergenheim, Anders Svenningsson

Summary: The study evaluated the effect of intrathecally delivered rituximab on PMS and found that it was well tolerated but did not halt disease progression.

JOURNAL OF NEUROLOGY (2021)

Article Biochemistry & Molecular Biology

Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing

Henrik Carlsson, Niclas Rollborn, Stephanie Herman, Eva Freyhult, Anders Svenningsson, Joachim Burman, Kim Kultima

Summary: This study analyzed the metabolomes of healthy individuals' CSF and identified ten metabolites significantly associated with ageing, with eight increasing with age and two decreasing with age. These findings contribute to the field of ageing metabolomics and provide motivation for further in-depth research.

METABOLITES (2021)

Editorial Material Clinical Neurology

Perinatal Depression and Anxiety in Multiple Sclerosis Treatable Distress

Victoria M. Leavitt, Ruth Dobson, Anders Svennigsson

NEUROLOGY (2021)

Article Clinical Neurology

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis Data From 2 Different National Strategies

Tim Spelman, Melinda Magyari, Fredrik Piehl, Anders Svenningsson, Peter Vestergaard Rasmussen, Matthias Kant, Finn Sellebjerg, Hanna Joensen, Jan Hillert, Jan Lycke

Summary: This study investigated the association between national differences in treatment strategies for RRMS and disability outcomes, finding that the Swedish treatment strategy was associated with reduced rates of disability worsening compared to the Danish strategy.

JAMA NEUROLOGY (2021)

Article Clinical Neurology

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Anders Svenningsson, Thomas Frisell, Joachim Burman, Jonatan Salzer, Katharina Fink, Susanna Hallberg, Joakim Hambraeus, Markus Axelsson, Faiez Al Nimer, Peter Sundstrom, Martin Gunnarsson, Rune Johansson, Johan Mellergard, Igal Rosenstein, Ahmad Ayad, Irina Sjoblom, Anette Risedal, Pierre de Flon, Eric Gilland, Jonas Lindeberg, Fadi Shawket, Fredrik Piehl, Jan Lycke

Summary: Rifund-MS study provides evidence that rituximab is superior to dimethyl fumarate in preventing relapses in patients with early relapsing-remitting multiple sclerosis. Adverse events such as infusion reactions and gastrointestinal reactions were observed, but there were no safety concerns.

LANCET NEUROLOGY (2022)

Editorial Material Clinical Neurology

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary

Jan Lycke, Anders Svenningsson

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

COVID-19 clinical outcomes and DMT of MS patients and population-based controls

Elisa Longinetti, Hannah Bower, Kyla A. McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergard, Tomas Olsson, Fredrik Piehl, Thomas Frisell

Summary: This study investigated the risks and associations with disease-modifying therapies in multiple sclerosis patients during the COVID-19 pandemic. The results showed that multiple sclerosis patients had increased risks for COVID-19 and other severe outcomes compared to population controls, but these risk increases were not significantly different from previous years. The risk conveyed by disease-modifying therapies was smaller than previously assumed, likely due to better control for confounding factors.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Medicine, General & Internal

Cerebral microvascular injuries in severe COVID-19 infection: progression of white matter hyperintensities post-infection

Ida Petersson, Bjorn M. Hansen, Anders Svenningsson, Annika Lundstrom

Summary: Neuroradiological findings in COVID-19 patients can resemble cerebral small vessel disease (CSVD). We present a case of a severe COVID-19 patient who showed white matter abnormalities and restricted diffusion on MRI. The patient experienced significant clinical recovery but MRI showed progression of the white matter abnormalities.

BMJ CASE REPORTS (2022)

Article Clinical Neurology

Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis

H. Tedeholm, F. Piehl, J. Lycke, J. Link, L. Stawiarz, J. Burman, P. de Flon, K. Fink, M. Gunnarsson, J. Mellergard, P. Nilsson, P. Sundstrom, A. Svenningsson, H. Johansson, O. Andersen

Summary: This study examined the impact of disease-modifying therapies (DMTs) on the risk of transition to secondary progressive MS (SPMS) using nationwide population-based data in Sweden. The results showed that the introduction of DMTs significantly decreased the incidence of SPMS conversion. The age at onset played a role in determining the risk of SPMS, and this pattern was observed in both treated and untreated subgroups.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS

L. Novakova, M. Axelsson, C. Malmestrom, H. Zetterberg, K. Blennow, A. Svenningsson, J. Lycke

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

暂无数据